Real-world individual patient-level analysis for mavacamten in obstructive hypertrophic cardiomyopathy: multi-domain response, safety and cyp2c19 genotype effects

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Hypertrophic obstructive cardiomyopathy: treatment, monitoring, and outcomes Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by